The upgrade from 'reduce' to 'buy' is based on a more optimistic view of the company's custom synthesis segment.

Eli Lilly and Johnson & Johnson, PPH’s largest holdings, are facing unique challenges, impacting the ETF’s overall ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

Layoffs have become a common business practice, but research shows long-term performance actually declines after layoffs.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...